Respiratory - chronic obstructive pulmonary disease
About ICLUSIG®
-
Marketed by Takeda Pharmaceutical Company Limited
-
Orally bioavailable Bcr-Abl tyrosine kinase inhibitor
-
Treatment of adult patients with treatment-resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML), accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome–positive (Ph+) CML for which no other kinase inhibitors are indicated, and T315I-positive CML or T315I-positive Ph+ ALL